22 February, 2017

Michael Clayman, M.D., CEO of Flexion Therapeutics talk about the need for new treatment options for osteoarthritis (OA) and Flexion’s lead investigational product candidate, ZilrettaTM

This morning, Michael Clayman, M.D., CEO of Flexion Therapeutics (Nasdaq: FLXN), appeared live on Fox Business News to talk about the need for new treatment options for osteoarthritis (OA) and Flexion’s lead investigational product candidate, ZilrettaTM (FX006) which is being evaluated as a potential new therapy for OA related knee pain. A link to Mike’s interview can be found below:

http://finance.yahoo.com/video/developing-alternatives-opioids-relieve-pain-130004965.html

Michael Clayman, M.D., CEO of Flexion Therapeutics talk about the need for new treatment options for osteoarthritis (OA) and Flexion’s lead investigational product candidate, ZilrettaTM

Purespring Therapeutics advances kidney-targeted gene therapy PS-003 towards the clinic in X-linked Alport Syndrome

DMC Secures $18M to Expand Health Ingredients Business

CorWave completes enrollment in feasibility study and presents first clinical data on adaptive support with its Wave Membrane LVAD

Muna Therapeutics announces positive Phase 1 results supporting potential of oral small-molecule TREM2 Modulator in Alzheimer’s disease

TISSIUM® receives CE Mark for ECLIPSIUM®, Its atraumatic hernia repair solution

F2G and Shionogi report data from Global Phase 3 OASIS Study evaluating investigational oral Olorofim versus AmBisome